- Home
- BWAY vs NYXH Comparison
BWAY vs NYXH Comparison
Compare BWAY & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWAY
- NYXH
- Stock Information
- Founded
- BWAY 2003
- NYXH 2009
- Country
- BWAY Israel
- NYXH Belgium
- Employees
- BWAY N/A
- NYXH N/A
- Industry
- BWAY Medical/Dental Instruments
- NYXH Medical/Dental Instruments
- Sector
- BWAY Health Care
- NYXH Health Care
- Exchange
- BWAY Nasdaq
- NYXH Nasdaq
- Market Cap
- BWAY 245.2M
- NYXH 222.3M
- IPO Year
- BWAY 2019
- NYXH 2021
- Fundamental
- Price
- BWAY $13.00
- NYXH $7.70
- Analyst Decision
- BWAY Strong Buy
- NYXH Strong Buy
- Analyst Count
- BWAY 2
- NYXH 4
- Target Price
- BWAY $14.25
- NYXH $14.50
- AVG Volume (30 Days)
- BWAY 53.7K
- NYXH 34.2K
- Earning Date
- BWAY 08-05-2025
- NYXH 08-05-2025
- Dividend Yield
- BWAY N/A
- NYXH N/A
- EPS Growth
- BWAY N/A
- NYXH N/A
- EPS
- BWAY 0.08
- NYXH N/A
- Revenue
- BWAY $43,457,000.00
- NYXH $4,716,818.00
- Revenue This Year
- BWAY $351.53
- NYXH $323.07
- Revenue Next Year
- BWAY $21.84
- NYXH $204.30
- P/E Ratio
- BWAY $64.24
- NYXH N/A
- Revenue Growth
- BWAY 26.86
- NYXH N/A
- 52 Week Low
- BWAY $5.98
- NYXH $5.55
- 52 Week High
- BWAY $13.66
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- BWAY 65.17
- NYXH 54.93
- Support Level
- BWAY $12.76
- NYXH $7.30
- Resistance Level
- BWAY $13.66
- NYXH $8.03
- Average True Range (ATR)
- BWAY 0.51
- NYXH 0.27
- MACD
- BWAY 0.02
- NYXH -0.01
- Stochastic Oscillator
- BWAY 76.73
- NYXH 65.75
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.